What medication properties increase or decrease their delirium‑inducing potential?

Medication Properties That Influence Delirium Risk

Medications become more deliriogenic primarily through anticholinergic activity, GABAergic enhancement (benzodiazepines), and histamine receptor antagonism, while the number of medications (polypharmacy) amplifies risk independent of specific drug classes.

Key Pharmacologic Properties That Increase Delirium Risk

Anticholinergic Activity

• Anticholinergic medications carry a three-fold increased risk of delirium (OR: 3.11,95% CI 1.04-9.26), representing the strongest evidence for a specific pharmacologic mechanism 1.
• The anticholinergic burden is cumulative—each medication with anticholinergic properties adds to the total risk, though one ICU study using the Anticholinergic Drug Scale found this relationship less clear in critically ill patients 2.
• Anticholinergic drugs have been consistently associated with delirium across multiple healthcare settings, including nursing homes 3.

GABAergic Enhancement

• Benzodiazepines are strongly associated with delirium (OR: 3.0,95% CI 1.3-6.8) and represent one of only two modifiable risk factors with strong evidence 4.
• Benzodiazepine use is one of the two modifiable factors with the highest quality evidence for delirium association in ICU patients 5.
• Benzodiazepines, antipsychotics, and H2-receptor antagonists were the most implicated deliriogenic medications in hospitalized older adults 6.

Opioid Receptor Agonism

• Opioids show an increased delirium risk (OR: 2.5,95% CI 1.2-5.2), though the evidence quality is lower than for benzodiazepines 4.
• Critical caveat: Untreated severe pain itself triggers delirium, so opioid avoidance must be balanced against adequate pain management 5, 4.
• Opioid use has been strongly shown NOT to alter delirium risk in some ICU studies, highlighting conflicting evidence 5.

Histamine Receptor Antagonism

• H1-antihistamines may increase delirium risk (OR: 1.8,95% CI 0.7-4.5), though evidence remains inconclusive 4.
• H2-receptor antagonists are frequently implicated clinically but have only low-quality evidence supporting the association 6.

Calcium Channel Blockade

• Dihydropyridine calcium channel blockers show increased risk (OR: 2.4,95% CI 1.0-5.8) 4.

Properties That Do NOT Increase Delirium Risk

Antipsychotic Medications

• Haloperidol shows no increased delirium risk (OR: 0.96,95% CI 0.72-1.28) with high-quality evidence 1.
• Olanzapine actually shows a protective association (OR: 0.25,95% CI 0.15-0.40) 1.
• Neuroleptics overall do not increase risk (OR: 0.9,95% CI 0.6-1.3) 4.
• Moderate-quality evidence suggests antipsychotics may increase delirium onset risk in nursing homes, though this conflicts with other data 3.

Other Medications

• Ketamine shows no increased risk (OR: 0.72,95% CI 0.35-1.46) with moderate-quality evidence 1.
• Corticosteroids show no increased risk (OR: 0.69,95% CI 0.32-1.50) with moderate-quality evidence 1.
• Digoxin appears protective (OR: 0.5,95% CI 0.3-0.9) 4.

Polypharmacy as an Independent Risk Factor

• The total number of medications matters independent of specific drug classes 5.
• Medication reviews should address both the type and number of medications, with consideration of discontinuing one medication when adding another long-term therapy 5.
• Patients who developed delirium tended to have more deliriogenic medications used during admission 6.
• The interaction between drug classes, doses, combinations, and number of agents makes polypharmacy evidence difficult to interpret 5.

Clinical Application Algorithm

For Prevention:

1. Avoid new benzodiazepine prescriptions in at-risk patients—this has the strongest evidence 5, 4.
2. Reduce or stop existing benzodiazepines where clinically feasible 4.
3. Calculate cumulative anticholinergic burden and minimize medications with anticholinergic properties 1.
4. Use opioids cautiously but do not withhold for pain management, as untreated pain is itself a delirium trigger 5, 4.
5. Exercise caution with dihydropyridines and H1-antihistamines in high-risk patients 4.
6. Conduct medication reviews for all at-risk patients, focusing on deprescribing when possible 5.

Medications to Prioritize for Deprescribing:

• Focus deprescribing efforts on benzodiazepines and anticholinergics, which have higher-quality evidence, rather than H2-receptor antagonists with lower-quality evidence 6.

Important Caveats

• Seventy-three percent of deliriogenic home medications are continued upon hospital admission, representing a missed prevention opportunity 6.
• The evidence for many medication classes (tricyclic antidepressants, antiparkinson medications, steroids, NSAIDs, antimuscarinics) remains uncertain and requires individual patient assessment 4.
• Age and acute systemic inflammation do not appear to modify the anticholinergic-delirium relationship 2.
• Blood transfusion administration is the other modifiable factor (besides benzodiazepines) with strong evidence for delirium association 5.